News und Analysen

Illumina, Inc. (NASDAQ: ILMN) has committed US $60 million in sequencing capabilities to a global pathogen genomics initiative, in partnership with the Bill & Melinda Gates Foundation and other

Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening

Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021, after the markets

LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2021.

For the first quarter of 2021, worldwide

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24^th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2021 financial results after the market closes

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2021.

First quarter results reflect record revenue:

• 
  Revenue of $1,093 million, a 27%

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2021.

First quarter results reflect record revenue:

• 
  Revenue of $1,093 million, a 27%

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2021.

First quarter results reflect record revenue:

• 
  Revenue of $1,093 million, a 27%

Regulatory News:

Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021.

In connection with the earnings release

Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2021

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, and Verily, a subsidiary of Alphabet focused on life sciences and healthcare, today announced that the first

Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.19 per share of Class A common stock issued and

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced additional data at a late-breaking session at the American Academy of Dermatology VMX Experience. Etrasimod, a novel investigational drug

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today preliminary results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 6, 2021, following the release of its first quarter

Illumina, Inc. (NASDAQ: ILMN) and Kartos Therapeutics, Inc. are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina’s

Illumina, Inc. (NASDAQ: ILMN) and Kartos Therapeutics, Inc. are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina’s

Illumina, Inc. (NASDAQ: ILMN) and Kartos Therapeutics, Inc. are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina’s

(Unaudited data)

Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial